CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

Yao Wang, Meixia Chen, Zhiqiang Wu, Chuan Tong, Hanren Dai, Yelei Guo, Yang Liu, Jianhua Huang, Haiyan Lv, Can Luo, Kai-chao Feng, Qing-ming Yang, Xiao-lei Li, and Weidong Han
Department of Molecular & Immunology, Chinese PLA General Hospital, Beijing, China; bDepartment of Bio-therapeutic, Chinese PLA General Hospital, Beijing, China

ABSTRACT
Expressed by cancer stem cells of various epithelial cell origins, CD133 is an attractive therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed CD133 (CART-133) was first tested in this trial. The anti-tumor specificity and the postulated toxicities of CART-133 were first assessed. Then, we conducted a phase I clinical study in which patients with advanced and CD133-positive tumors received CART-133 cell-infusion. We enrolled 23 patients (14 with hepatocellular carcinoma (HCC), 7 with pancreatic carcinomas, and 2 with colorectal carcinomas). The 8 initially enrolled patients with HCC were treated by a CART-133 dose escalation scheme (0.05–2 × 10^6/kg). The higher CAR-copy numbers and its reverse relationship with the count of CD133+ cells in peripheral blood led to the determination of an acceptable cell dose is 0.5–2 × 10^6/kg and reinfusion cycle in 23 patients. The primary toxicity is a decrease in hemoglobin/platelet (≤ grade 3) that is self-recovered within 1 week. Of 23 patients, three achieved partial remission, and 14 achieved stable disease. The 3-month disease control rate was 65.2%, and the median progression-free survival was 5 months. Repeated cell infusions seemed to provide a longer period of disease stability, especially in patients who achieved tumor reduction after the first cell-infusion. 21 out of 23 patients had not developed detectable de novo lesions during this term. Analysis of biopsied tissues by immunohistochemistry showed CD133+ cells were eliminated after CART-133 infusions. This trial showed the feasibility, controllable toxicities, and effective activity of CART-133 transfer for treating patients with CD133-positive and late-stage metastasis malignancies.

ARTICLE HISTORY
Received 19 December 2017
Revised 1 February 2018
Accepted 6 February 2018

KEYWORDS
Adoptive T cell therapies; advanced metastasis malignancies; autologous T cells; CD133; chimeric antigen receptor (CAR); phase I trial; therapeutic trials

Introduction
In recent years, chimeric antigen receptor-specific T (CAR-T) cells have emerged as a tool for the clinical treatment of cancers. T cells modified by CAR have a potent cellular effector mechanism, called HLA-independent recognition, to recognize and kill tumor cells expressing the corresponding antigen. Especially in B cell acute lymphoblastic leukemia (B-ALL), the target CD19-modified CAR-T cell therapy achieved a 74% to 90% complete remission rate. CAR-T cells targeting CD19 or CD20 have also shown encouraging antitumor activity in relapsed or refractory B-cell lymphomas. In solid tumors, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2, disialoganglioside 2, and mesothelin and interleukin-13 Ra2 are current targets of CAR-T cells. Although the strategy for the use of CAR-T cells has been shown to be safe and effective in the treatment of B-ALL it has not yet been shown same effective for solid tumors as for hematologic malignancies.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related morbidity and mortality. Despite evaluation of many chemotherapy and targeted therapy agents, the only proven treatments for advanced disease are sorafenib, regorafenib, and lenvatinib, and overall survival benefits are modest. Addition, liver metastases may escape immune surveillance due to the immunosuppressive nature of the intrahepatic space, and once the tumor metastasizes to the liver, a poor prognosis is suggested. China also has a relatively high incidence of liver cancer. Clinical trials being conducted in China are evaluating MG7 and EpCAM antigen-targeted CAR-T cells in liver cancer.

CD133 is a pentaspan transmembrane glycoprotein that is overexpressed in various solid tumors. CD133 was found here to be highly expressed in 50% of case of HCC, pancreatic cancer, gastric cancer, and intrahepatic cholangiocarcinomas. Especially for HCC, high CD133 expression in HCC cells corresponds with higher stage tumors, and indicating a poor prognosis for most patients. Moreover, CD133 is a marker of cancer stem cells (CSCs) and endothelial progenitor cells (EPCs) that had been verified to participate in tumor metastasis and recurrence. These characteristics make CD133 a reasonable target for immunotherapy for patients with advanced CD133-positive tumors.

In this study, we have developed a CD133-specific CAR-modified T cell, termed CART-133. This CAR T eliminates CD133-
expressing tumors in vitro and in a xenograft tumor model. Then, we are conducting a clinical trial to assess the antimalignancy efficacy, feasibility, and toxicity of CART-133 cells in patients with advanced HCC or other malignancies with liver metastases, and no serious adverse events were observed.

Methods

Patients

This study was an open-label and single-arm phase I trial (ClinicalTrials.gov identifier: NCT02541370) that was approved by the Institutional Review Board at the Chinese PLA General Hospital. Adult patients (aged 18–70 years) were eligible for inclusion if they had a diagnosis of progressive disease (PD) of CD133-positive HCC or solid malignant tumor with multiple metastases based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) after receiving at least two previous systemic therapies. Primary exclusion criteria were severe organ dysfunction, a history of or active systemic autoimmune/immunodeficiency disease, and a treatment history of immunosuppressive agents or glucocorticoids within a month of the study. All patients provided written informed consent before enrolling in the study.

Generation and transduction of CART-133 cells

(1) Generation of lentiviral.
CART-133 containing anti-CD133 scFv derived from HW350341.1, human CD137 and CD3z signaling domains (Fig. 1A). The CAR construct was verified by DNA sequencing. A pseudotyped, clinical-grade lentiviral vector supernatant was produced by standard transient transfection as McGinley et al. described. According to the manufacturer’s instructions, Lipofectamine 3000 transfection reagent (Invitrogen, USA), pWPT-anti-CD133 CAR plasmid, ps-PAX2 packaging plasmid, and pMD2.G envelope plasmid were transfected into 293 T cells. The lentiviral supernatants were collected and stored at −80°C.

(2) Generation of CART-133 Cells.
CART-133 cells were generated as previously described.7,22–24 Briefly, PBMCs from the 80–100 ml fresh blood were directly suspended in the GT-T551 medium (Takara, Japan) with the anti-CD3 mAb (500 ng/ml) and IL-2 (interleukin-2) (300 U/ml) (Peprotech, USA). Lentiivirus-mediated CAR transduction was performed on day 3 of cell culture in six-well plates precoated with a recombinant fibronectin fragment. After transduction, the cells were expanded ex vivo in the presence of IL-2 added three times weekly until the specified cell dose achieved.

Study description and clinical response criteria

All patients had imaging with computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography to assess overall disease burden before CART-133 cell infusion. Peripheral blood (PB) samples were obtained before CART-133 cell infusion and at predetermined time points after infusion to evaluate the activity of CART-133 cells and toxicity. In the initial phase of the study, patients1 to 8

Figure 1. Treatment plan and treatment protocol. (A) Schematic representation of the CAR-133-CD37z chimeric T-cell receptor cDNA plasmid, not to scale. (B) Consort flow diagram of the clinical trial. (C) One standard cycle of CART-133 treatment procedure. CART-133 treatment for non-HCC patients included a chemotherapy pre-regimen (red dashed line).
were enrolled in doses escalation scheme (Fig. 1B). HCC patients were not given conditioning treatment before cell infusion due to liver dysfunction and non-HCC patients were conditioned with cyclophosphamide (30 mg/kg) and nab-paclitaxel (150 mg/m2) conditioning treatment. Protocol details are shown in the study flow chart (Fig. 1C). Patients were eligible to receive an additional cell treatment cycle if they could tolerate the toxicity and had a clinical benefit. The second treatment cycle was performed at least 4 weeks after the first infusion. All patients were recruited to receive CART-133 cell therapy and to undergo follow-up between June 15, 2015, and June 30, 2017.

Clinical response was evaluated by using contrast-enhanced computed tomography (CT) or and magnetic resonance imaging (MRI) and performed 1 month after the cell infusion. The clinical responses were defined according to Response Evaluation Criteria in RECIST 1.1 and immune-related response criteria. Adverse events were documented and graded based on the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0). Cytokines release syndrome (CRS) graded and managed based on a previous report from Lee et al. Dose-limiting toxicity (DLT) was defined as any grade 3 or above toxicity that would be resolved to grade 2 within 2 weeks of onset; infusion-related toxicities (within 24 hours); grade 3 diarrhea, nausea, and anorexia that would be resolved to grade 2 within 2 weeks; grade 3 CRS that would be resolved within 1 week; transient increase of grade 3 liver enzymes (<72 hours); and grade 3 fever lasting 1 week or less.

Flow cytometry analysis and cell sorting

Evaluation of CAR expression was performed by staining with a goat anti-mouse Fab antibody (Jackson ImmunoResearch, USA). In addition, the following anti-human antibodies were also used in this study: CD133 (phycoerythrin, PE), CD3 (chlorophyll protein complex PerCP), CD4 (fluorescein isothiocyanate, FITC), CD8-PE, CD45RO (allophycocyanin, APC), CD56-APC, CD62 L-PE, and CCR7-PE-Cy7 were purchased from Becton Dickinson. Isotype-matched control mAbs were applied in all the procedures. FACS data were analyzed by a FACS Calibur flow cytometer (BD Biosciences) and FlowJo software (Version 10.0.7, FlowJo, Ashland, OR).

Quantitative real-time PCR

Real-time quantitative polymerase chain reaction (Q-PCR) was used to assess the level of the CAR fusion genes according to a previously described protocol. A 153-bp (base pair) fragment containing portions of the CD8 a chain and adjacent CD137 chain was amplified using forward primer 5'-GTTCCCTTCCTGCAGTCTTTGG-3' and reverse primer 5'-CTTTGTTTCTTCTGG AAATGGGGCAG-3'to detect the CAR gene; amplification of β-actin was used as an internal control and for normalization of DNA quantities. Q-PCR was performed using SYBR Green Master Mix (Toyobo, Japan) and run on an ABI prism 7500 sequence detection system (Applied Biosystems). A 7-point standard curve that consisted of 100 to 10^8 copies/μL plasmid DNA containing the CAR gene was prepared.

The expression of the CD133 gene in PBMC from patients was detected by Q-PCR. Total RNA was isolated from peripheral blood using Trizol reagent (Takara, Japan) and reverse transcribed into cDNA using the cDNA Synthesis Kit (Takara, Japan) according to the manufacturer’s protocol. The following primers (forward and reverse primers) were used: CD133 (5'-GGCAAGCCGATCAAGGAG-3' and 5'-GTGGATGTCACCAAGCAG-3') and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (5'-GTGGAGTCCACCTGGCCTTT-3', and 5'-GTCGAGGAGGCATTGCTGAT-3'). The relative fold change in expression was calculated by normalizing against GAPDH to adjust for loading variation.

Cytokine measurements

Serum IL-2, IL-6, IL-8, IL-10, IFN-γ, TNF-α levels were batch analyzed using a BD Biosciences microbead sandwich immunoassay according to the manufacturer’s instructions. Briefly, analyte concentration was determined using a standard curve prepared with each assay.

Statistical analysis

The results are shown as the mean ± standard error of the mean (SEM) of triplicate determinants (wells). Data were plotted using GraphPad Prism version 6.0. Two-way analysis of variance (ANOVA) was used to determine the significance of the differences between the means in all experiments. The survival curve and progression-free survival (PFS) were determined by the Kaplan-Meier method. P value < 0.05 was considered to be statistically significant. Detailed descriptions of statistical analyses are provided in Supplement Methods.

Results

CART-133 exhibits enhanced antitumor activity against CD133⁺ cell line

CART-133 cells used for in vitro experiments and animal models were generated from three healthy donors. Mean transfection efficiencies of 34.22% ± 4.00% and 32.95% ± 4.76% were verified in the final CART-133 and mock T-cell populations, respectively (Supplement Fig. 1). Six kinds of tumor-cell lines (SW1990, HT29, DLD1, SW480, Hep3B, and LOVO) were divided into three groups (high, medium, and negative expression of CD133). CART-133 cells showed remarkable lysis ability and produced higher cytokines than to mock and NT (non-transduced T) cells against CD133⁺ cells but not CD133⁻ cells after co-culture for 8 hours (Supplement Fig. 2). The subcutaneous xenotransplanted tumor model of CD133⁺ cells was established in BALB/c nude mice. As shown in Supplement Fig. 3, tumor growth was significantly inhibited and
the high level of CAR-gene copy in tumor tissue was detected in the CART-133 cell group compared to other groups. ($p < 0.05$)

**Patient characteristics**

Twenty-three patients were enrolled in this study. The clinical and disease-specific characteristics of patients are listed in Table 1. Their median age was 56 years (range, 36–66 years). Fourteen patients had received a diagnosis of advanced HCC, 7 patients had advanced pancreatic cancer, and the other 2 patients had advanced colorectal cancer. CD133 positivity was confirmed by immunohistochemistry, as shown in Supplement Table 1. All patients had refractory/recurrent metastatic advanced disease and had experienced treatment failure with two or more conventional regimens. Twenty-two patients had stage IV carcinoma. Twelve patients had their primary lesion removed by surgery and presented with metastasis primarily in the lymph node, liver, and a wide range of anatomic sites. In HCC patients, 12 had sorafenib resistance, 10 had bulky disease burdens (lesion diameter > 10 cm), and 9 had portal vein tumor thrombus.

**Generation and characterization of CART-133 cells**

CART-133 cells were successfully generated from each patient. A mean of 95.254 ± 7.286% of the infused cells were CD3+ cells principally composed of CD8+ subset (62.906 ± 18.834%). The transduction efficiency ranged from 11.23% to 56.47%. Approximately 26.425% ± 14.395% of the total cell population was Tcm (central memory cells) (CD3+ /CD45RO+/CD62L−/CCR7+; range: 6.34%–63.48%). The detailed data of infused cells for each patient are summarized in Supplement Table S2 and Fig. 4.
The 8 initially enrolled patients were involved in dose-escalation scheme. Patients 1 to 3 in cohort 1 received CART-133 cells for a cell dose range of $0.05-0.15 \times 10^6$/kg (Fig. 2). Although no obvious adverse reactions occurred after CART-133 cell infusion for up to 1 month, all patients had no obvious decrease in CD133 cells and an increase in CAR-gene copy numbers in PB; the results of cytokines and tumor markers also had no distinct fluctuations (Fig. 2). Therefore, the dose of cohort 1 was closed because it was noneffective, and then the treatment dose of CART-133 cells was then amended in subsequent cohorts. Three patients in cohort 1 and patient 4 were eligible to receive doses of CART-133 cells in cohort 2 ($0.5-1.0 \times 10^6$/kg). After cell infusion, all patients experienced mild (≤ Grade 2) hematologic toxicities and self-recovered within 1 week. In addition, increased CAR-gene copy number and reduced CD133<sup>+</sup> cells in PB occurred in all four patients after cell infusion; two kinds of tumor markers were decreased in patients 3 and 4 (Fig. 2). Based on cohort 2’s effective clinical immune response and tolerated/recovery toxicities, the CART-133 cell dose was increased to $1.0-2.0 \times 10^6$/kg for patients 5 to 8 in cohort 3. Similar toxicities and effective activity were all observed in cohort 3 (Fig. 2). No DLT was observed in cohorts 2 and 3. These results determined the acceptable CART-133 cell dose was $0.5$ to $2 \times 10^6$/kg, which was subsequently used in the additional 15 patients. All further analyses started from the completed effective dose (excluding cohort-1) in this study.

**CART-133 cell dose escalation scheme**

In this trial, 3 patients received two cell cycles, and 9 patients received three to four cycles (Table 2 and Fig. 2A). Patients received a mean of $1.43 \times 10^6$/kg CAR-positive T-cells (range, $0.5-2.0 \times 10^6$/kg) in total during the infusion. All toxicities except infusion-associated toxicities are listed in Table 2 and Supplement Table S3. Nearly all the patients experienced reduction of hemoglobin, lymphocytes, and thrombocytes. Hematologic toxicities generally occurred 3 to 5 days after cell-infusion and self-recovered within 1 week. All the non-HCC patients experienced grade 2–4 lymphopenia whereas all HCC patients had less than grade 2. In particular, grade 3 adverse event (AE) that lasted 3 weeks with hyperbilirubinemia (direct

**Administration and safety of CART-133 cells**

In this trial, 3 patients received two cell cycles, and 9 patients received three to four cycles (Table 2 and Fig. 2A). Patients received a mean of $1.43 \times 10^6$/kg CAR-positive T-cells (range, $0.5-2.0 \times 10^6$/kg) in total during the infusion. All toxicities except infusion-associated toxicities are listed in Table 2 and Supplement Table S3. Nearly all the patients experienced reduction of hemoglobin, lymphocytes, and thrombocytes. Hematologic toxicities generally occurred 3 to 5 days after cell-infusion and self-recovered within 1 week. All the non-HCC patients experienced grade 2–4 lymphopenia whereas all HCC patients had less than grade 2. In particular, grade 3 adverse event (AE) that lasted 3 weeks with hyperbilirubinemia (direct
Table 1. Characteristics of patients (n = 23).

| Patient No. | Gender | Age (years) | Diagnosis/Stage | Histology/Grading | Metastatic lesion | Max diameter | ECOG | The prior therapies |
|-------------|--------|-------------|-----------------|-------------------|-------------------|--------------|------|-------------------|
| 1           | Male   | 58          | HCC/IV          |                  | Lymph node       | YES          | >10 cm | 2                 |
| 2           | Female | 66          | HCC/IV          |                  | Bone, Lymph nodes| NO           | 5-6 cm | 2                 |
| 3           | Male   | 53          | HCC/IV          |                  | Lung, Bone, Lymph nodes | NO           | >10 cm | 2                 |
| 4           | Male   | 57          | HCC/IV          |                  | Lung, Bone, Lymph nodes | YES          | >10 cm | 2                 |
| 5           | Male   | 57          | HCC/BDC/IV      |                  | Bone, Lymph nodes | YES          | >10 cm | 2                 |
| 6           | Male   | 57          | HCC/IV          |                  | Lung, Lymph nodes | YES          | 4-5 cm | 1                 |
| 7           | Male   | 64          | HCC/IV          |                  | Lymph nodes      | YES          | >10 cm | 0                 |
| 8           | Male   | 53          | HCC/IV          |                  | Lymph nodes      | YES          | diffused | 2                 |
| 9           | Male   | 52          | HCC/IV          |                  | Lung, Bone, Lymph nodes | YES          | >10 cm | 1                 |
| 10          | Male   | 48          | HCC/IV          |                  | Lung nodes       | YES          | >10 cm | 0                 |
| 11          | Male   | 46          | HCC/IV          |                  | Lymph nodes      | YES          | >10 cm | 2                 |
| 12          | Male   | 36          | HCC/IV          |                  | None             | NO           | 3-4 cm | 0                 |
| 13          | Male   | 47          | HCC/IV          |                  | Lung, Bone, Lymph nodes | YES          | >10 cm | 2                 |
| 14          | Male   | 47          | HCC/IV          |                  | Bone, Lymph nodes | YES          | >10 cm | 1                 |

Disease burden at baseline

| Patient No. | Gender | Age (years) | Diagnosis/Stage | Histology/Grading | Metastatic lesion | Max diameter | ECOG | The prior therapies |
|-------------|--------|-------------|-----------------|-------------------|-------------------|--------------|------|-------------------|
| 15          | Male   | 58          | MPC/IV          | AdenoCA/2-3       | Lymph nodes, Liver, Bone | 4 cm          | 1    | CIK × 1, PD-1,N-p,GE+S1 |
| 16          | Male   | 66          | MPC/IV          | AdenoCA/2-3       | Bone, Lymph nodes, Liver | 1 cm          | 0    | Surgery,TACE × 1,GE+S1 × 4, |
| 17          | Male   | 57          | MPC/IV          | AdenoCA/2-3       | Lymph nodes       | 1.5 cm        | 0    | Surgery,GE,Cap,N-p+GE |
| 18          | Male   | 57          | MPC/IV          | AdenoCA/2-3       | Lymph nodes, Liver | 4 cm          | 0    | Surgery,GE,N-p+GE |
| 19          | Male   | 56          | MPC/IV          | AdenoCA/2-3       | Lymph nodes, Liver, Bone | 4 cm          | 0    | CART-her1 × 3, radiotherapy, N-p+GE |
| 20          | Male   | 57          | MPC/IV          | AdenoCA/3         | Lymph nodes, Liver, | Diffused, 3.4 cm | 2    | Surgery, N-p+GE × 2, CART-her1 × 2 |
| 21          | Male   | 49          | MPC/IV          | AdenoCA/2         | Duodenum, Liver, Lymph nodes | 1.9 cm          | 0    | Surgery, Nimotuzumab GE+S1 × 4 |
| 22          | Male   | 53          | CRC/IV          | AdenoCA/2-3       | Lymph nodes, Liver | 3.5 cm        | 1    | Surgery,CIK × 1, FOLFOX,FOLFR1,N-p, GE+S1, Beacizumab |
| 23          | Male   | 54          | CRC/IV          | AdenoCA/2-3       | Lymph node, Liver | 2.7 cm        | 0    | Surgery, CIK × 17, FOLFOX,FOLFR1S1, Beacizumab |

HCC = hepatocellular carcinoma; MPC = metastatic pancreatic carcinoma; CRC = colorectal carcinoma; BCLC = Barcelona Clinic Liver Cancer; AdenoCA = adenocarcinoma; 2 = moderately differentiated; 3 = poorly differentiated; PVTT = portal vein tumor thrombus; ECOG = Eastern Cooperative Oncology Group; TACE = transcatheter arterial chemoembolization; PRFA = percutaneous radio-frequency ablation; PMCT = percutaneous microwave coagulation therapy for liver cancer; CIK = Cytokine-Induced Killer therapy; NKT = natural killer T cell therapy; PEIT = percutaneous ethanol injection therapy; CART = chimeric antigen receptor T-cell immunotherapy; PD-1 = Anti-PD antibody; GE = Gemcitabine; N-p = Paclitaxel For Injection (Albumin Bound); S1 = Tegafur, Gimeracil and Oteracil Potassium Capsules; FOLFOX = Oxaliplatin, leucovorin and 5-FU; FOLFIRI = Irinotecan, leucovorin and 5-FU.
bilirubin) was observed in three patients (4, 9, 22), who had an obstructed of the biliary tract accompanied by a high bilirubin background before cell infusion. Concentrations of plasma cytokines were determined after infusion by multiplex analysis at serial time points before and after CART-133 cell infusion (Fig. 3). There was a significant increase in the level of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and IL-8 at 1 and 2 weeks after cell infusion.

Overall clinical responses

As shown in Tables 2 and 3, the duration of responses in all patients currently ranges from 9 to 63 weeks. Three patients achieved PR, and 14 patients had SD for 9 weeks to 15.7 months (Fig. 4A), and 3 patients have a continued response at the time of this writing. HCC patients’ median PFS was 7 months, and the median PFS was 5 months in all patients (range, 2.0-15.2 months) (Fig. 4B). The 3-month disease control rate (DCR) was 65.2%, and the 6-month DCR was 30.4%. Tumor remission was observed in nine patients, and 21 patients had not developed detectable de novo metastatic lesions during the trial. In patients who achieved SD or PR after the first infusion, repeated cell infusion seems to have provided a longer period of disease stability (Fig. 4C).

Special presentations: (i) Patients 6 and 12 were the only 2 patients who had a lower tumor burden (lesion diameter <5 cm) among HCC patients. Patient 6 obtained the longest stable disease period (15.2 months), and patient 12 attained a 13.7-month ongoing SD by having three CART-133 monotherapies. (ii) Patient 14 had stable disease for 6 months, and then his tumor rapidly progressed with a 50% increase of the primary lesion after the third cell infusion. We were surprised to observe that the liver biopsy pre- and post-treatment presented a dramatic clearance of CD133+ tumor cells and a rapid proliferation of CD133-negative tumor cells (Fig. 5B). (iii) Patient 15 was diagnosed as having progressed stage IV pancreatic cancer accompanied by multiple metastases before cell treatment. His tumor was significantly reduced by approximately 40% after the first cell infusion, and he maintained this status for 4 months. A grade 2 CRS was first occurred after 1 week of the third cell infusion. The above data are shown in the Fig. 5C.

Bioactivity and persistent of CART-133 cells in vivo

(i) The reverse relationship between CART cells and CD133+ cells in PB was confirmed. The copy numbers of CAR-gene in PB reached their peak (646.1±257.1/μg gDNA) between 7 and 21 days in almost all patients. Meanwhile, during this period, CART-133 cells resulted in a significant decrease of the CD133+ cells and CD133...
Table 2. Patients' response and toxicity.

| Patient No. | Disease status at study entry | No. of CAR positive T cells infused (10^6/kg) at each treatment cycle | Response (month) | New metastatic lesions during treatment | Outcome Grade/C21 | Adverse events | Grade ≥ 2 toxicities |
|-------------|-------------------------------|---------------------------------------------------------------------|------------------|-----------------------------------------|-------------------|---------------|-------------------|
| 1           | PD                            | 1 st: 0.78                                                          | SD (4.25)        | None                                    | None              | None          | None              |
| 2           | PD                            | 1 st: 0.51                                                          | PD               | Spleen                                  | None              | None          | None              |
| 3           | PD                            | 1 st: 0.8                                                           | SD (3)           | None                                    | None              | None          | None              |
| 4           | PD                            | 1 st: 0.67                                                          | None             | Pr (3) SD (1.7) Abdominal wall          | None              | None          | None              |
| 5           | PD                            | 1 st: 1.01; 2 nd: 0.6                                               | SD (4.5)         | None                                    | None              | None          | None              |
| 6           | PD                            | 1 st: 1.0; 2 nd: 0.5                                                | SD (15.25)       | None                                    | None              | None          | None              |
| 7           | PD                            | 1 st: 1.8; 2 nd: 0.83                                               | SD (4)           | None                                    | None              | None          | None              |
| 8           | PD                            | 1 st: 1.98; 2 nd: 0.52; 3 rd: 1.34                                   | PR (3) SD (1.7)  | Abdominal wall                          | None              | None          | None              |
| 9           | PD                            | 1 st: 1.32                                                          | PD               | None                                    | None              | None          | None              |
| 10          | PD                            | 1 st: 0.67; 2 nd: 1.43                                               | PD               | None                                    | None              | None          | None              |
| 11          | PD                            | 1 st: 1.05                                                          | SD (2)           | None                                    | None              | None          | None              |
| 12          | PD                            | 1 st: 2.0; 2 nd: 2.0 3 rd: 1.5                                       | SD (13.7+)       | None                                    | None              | None          | None              |
| 13          | PD                            | 1 st: 0.85                                                          | PD               | None                                    | None              | None          | None              |
| 14          | PD                            | 1 st: 1.8; 2 nd: 1.0 3 rd: 0.8                                        | SD (6)           | None                                    | None              | None          | None              |
| 15          | PD                            | 1 st: 1.48; 2 nd: 1.67 3 rd: 2.0                                      | PR (4)           | None                                    | None              | None          | None              |
| 16          | PD                            | 1 st: 1.88; 2 nd: 1.67 3 rd: 1.92                                     | PR (3)           | None                                    | None              | None          | None              |
| 17          | PD                            | 1 st: 1.8                                                           | SD (3)           | None                                    | None              | None          | None              |
| 18          | PD                            | 1 st: 1.8                                                           | SD (3)           | None                                    | None              | None          | None              |
| 19          | PD                            | 1 st: 1.38; 2 nd: 1.67                                               | PD               | None                                    | None              | None          | None              |
| 20          | PD                            | 1 st: 1.72                                                          | None             | None                                    | None              | None          | None              |
| 21          | PD                            | 1 st: 1.43; 2 nd: 1.78 3 rd: 1.52                                    | SD (10.25+)      | None                                    | None              | None          | None              |
| 22          | PD                            | 1 st: 1.87                                                          | SD (2.2)         | None                                    | None              | None          | None              |
| 23          | PD                            | 1 st: 1.43; 2 nd: 1.79                                               | SD (15.7+)       | None                                    | None              | None          | None              |

Abbreviations: PR, regression of measurable disease (≥30% decrease) and no new sites; SD, stable disease; PD, progressive disease.
Table 3. CART-133 efficacy in all patients.

|                                | HCC patients (n = 14) | non-HCC patients (n = 9) | All patients (n = 23) |
|--------------------------------|------------------------|--------------------------|-----------------------|
| Objective response*            | 1 (7%)                 | 2 (22%)                  | 3 (13%)               |
| Complete response              | 0                      | 0                        | 0                     |
| Partial response               | 1 (7%)                 | 2 (22%)                  | 3 (13%)               |
| Stable disease                 | 9 (64%)                | 5 (56%)                  | 14 (61%)              |
| Progressive disease            | 4 (28%)                | 2 (22%)                  | 6 (26%)               |
| Disease control*               | 6 (43%)                | 2 (22%)                  | 8 (35%)               |
| Disease control with stable disease for ≥ 3 months | 9 (64%) | 6 (67%) | 15 (65%) |
| Overall survival 6 months      | 6 (43%)                | 2 (22%)                  | 8 (35%)               |
| Progression-free survival*     | 7 (0.5 to 4.3)         | 5 (0.2 to 1.9)           | 5 (0.4 to 3.0)        |

Unless otherwise indicated, data are n (%); months (95% CI). KM = Kaplan-Meier estimate. RECIST = Response Evaluation Criteria In Solid Tumors. *Determined by investigator assessment using RECIST version 1.1.

Figure 5. Special presentations. (A) Immunohistochemical examination (diaminobenzidine with hematoxylin counterstaining) of a punch biopsy of liver lesion from patient 12 before and 41 weeks after the first CART-133 cell infusion. (B) Immunohistochemical examination of patient 14 before and 30 weeks after the first CART-133 cell infusion showed that tumor cells were CD133− after cell infusion. Notably, scattered CD3+ and CD8+ cells infiltrated the tumor after infusion, and CD34+ cells significantly decreased. (C) Left: Representative tumor response images for patient 15 before and after CART-133 cell infusion, contrast-enhanced MRI scans show pancreas and liver lesions reduced significantly 4 weeks after the first CART-133 cell infusion and remained reduced after the second cell infusion. Right: CD133+ cells in PB, CAR-gene copy numbers in PB and cytokines in serum were detected before and at serial time points after CART-133 cell infusion in patient 15.
gene expression in PB (Fig. 6A and Supplement Fig. 5). CAR-gene copies decreased after approximately 4 weeks (Fig. 6B), but lower-level signals (364.4±117.8/µg gDNA) could be detected after more than 2 months in 7 patients. For repeated cell infusion, a peak of CAR-gene copies in PB was also observed in each cell cycle (Supplement Fig. 6).

(ii) T lymphocyte cell infiltration and CD133+ cell elimination in tumor lesions. Immunohistochemical staining of biopsies from two patients at 2 weeks after the third cell infusion demonstrated an increasing augmentation of CD3+ and CD8+ T cells scattered within tumor parenchyma; on the contrary, CD133+ cells were not detected in tumor tissue (Fig. 5A and B).

(iii) Antitumor ability of CART-133 cells is positively correlated with the cytokine secretion ability. During the 4 weeks after cell infusion, the median of increased fold change in IFN-γ, TNF-α, and IL-6 in patients who achieved more than 8 months of PFS was significantly higher than in the other patients (Fig. 6C).

Discussion
In this trial, our results exhibited the feasibility, safety, and efficacy of CART-133 in patients with advanced relapsed/refractory and metastatic tumor. Especially for HCC patients, previous studies in advanced HCC of first-line sorafenib have shown response rates of 2%–3%, and if patients whose
conditions failed to first-line treatment and sorafenib, the median overall survival (OS) is no more than 4 months.\textsuperscript{13} It was encouraging that HCC patients receiving CART-133 treatment have demonstrated median PFS of 7 months in our study; patients whose disease even failed to respond to first-line treatment and sorafenib might achieve relatively lengthy stable disease after CART-133 repeat infusion.

"On-target, off-tumor" effects are the most common side effects in the clinical application of CAR-T cells and result in an autoimmune response against normal tissues that express the targeted antigen in solid tumor therapies. CD133 was initially localized to CD34+ hematopoietic stem cells, and CD133 was also confirmed on the surface of CD34+ progenitor cells in adult bone marrow, umbilical cord blood, and PB.\textsuperscript{28} Hematopoietic system toxicities were observed in almost all patients in this study, including the reduction of hemoglobin, lymphocytes, and thrombocytes after cell infusion for 2 to 5 days. The first reported that grade 2 to 3 bilirubinemia occurred in 3 patients with underlying illness backgrounds of either bile duct stenosis or high levels of bilirubin in this study. Bilirubinemia toxicity may in part be attributable to CD133, which was confirmed to be a marker of endothelial cells in the lesions. CART-133 cells targeted on CD133 antigen expressed on the bile duct endothelium in vivo after cell infusion, inducing an immune response that resulted in the release of inflammatory factors, increased bile duct blockage, and in turn, increased direct bilirubin secretion and caused severe toxicity. On the other hand, in this study, five HCC patients had lung metastasis, 7 pancreatic cancer patients and 2 colorectal carcinoma patients with lymph node metastasis in this study, and no obvious inflammatory response was observed in the liver, lung, pancreatic, colo-rectal, and multiple lymph nodes of these patients. So, this serious "on-target, off-tumor" effect of CART-133 seems to have occurred only in patients with bile duct stenosis. Given that the serious toxicity was different from that in other reports, CART-133 cell therapy must be approached with great caution in patients with a background of bile duct stenosis.

Persistence was the most common problem in the treatment of solid tumors by CART. We showed that CART-133 cells may persist for a long period in vivo by repeat infusion, and persistence of CAR-gene may achieve effective disease clearance and protection from recurrence. Some studies have reported that the second anti-CD19 CAR-T cell infusion did not achieve amplified peak as it had in the first infusion in vivo. One mechanism is that CD19 is still present but cannot be detected and recognized by CART-19 cells as its cell surface fragment containing cognate epitope is absent due to deleterious mutation and alternative splicing.\textsuperscript{29} The other probable mechanism, a cellular immune response specific for murine scFV epitopes, of anti-CD19 CAR formed, resulting in the failure of the second infusion.\textsuperscript{30,31} In this study, the peak of amplification of the CAR-gene can be detected after CART-133 repeat infusion, and the CD133+ cells in patients' PB was sustained at low levels. These results suggest that the homologous CD133 epitopes of the cell surface may not be prone to mutations, and patients have low probability to produce a humoral immune response to the CAR with murine scFV after receiving repeated CART-133 infusion; repeated infusions can extend the presence of CART-133 in vivo. In the previous study, CRS and tumor lysis symptoms correlated with the tumor burden at the time of the infusion of the CAR-directed T cells.\textsuperscript{32,33} On the other hand, patients 6 and 12 were the only patients who had a lower-load tumor among HCC patients; they both achieved longer stable disease than other HCC patients, which suggested the superiority of CART-133 cell treatment for HCC patients with lower tumor burden, as was endorsed by previous reports.\textsuperscript{34,35} These findings suggested that the CART cells were used in patients earlier in the course of their disease or immediately after surgery help eliminate the minimal residual disease and reduce the chance for recurrence. It is noteworthy that the 1-month DCR of non-HCC patients with a pre-treated regimen is 100%. Many mechanisms have been proposed to underline the enhanced in vivo antitumor activity of transferred T cells through prior conditioning chemotherapy. Lymphocytes and interstitial cell clearance can contribute to the expansion of CART cells in vivo and infiltrate the solid tumor.\textsuperscript{36,37} Therefore, lymphocyte clearance and reduced tumor load conditioning regimens are necessary under the premise that patients can tolerate a conditioning chemotherapy regimen to enhance the CART-133 antitumor effect in vivo.

Many studies have shown that the high level of CD133 predicts a poor prognosis in human HCC patients, is associated with lower survival rate, and also positively correlates with a high level of microvessel density and CD34+ cells infiltration in the tumor bed.\textsuperscript{18,19} On the other hand, CD133 is currently the most mature surface marker on EPCs, and EPCs have been shown to have important correlations with tumor recurrence and distal metastasis.\textsuperscript{36,37} We found that patients seem can achieved long-term stability without new metastasis presented. It suggested that CART-133 cells seem to effectively affect the occurrence of new metastasis by reducing the angiogenesis in the tumor and the number of EPC in vivo. These results need to be further confirmation in future clinical trials with large samples.

Tumor antigen heterogeneity is an important factor limiting CART’s efficacy in solid tumors. In this study, puncture specimens of two patients showed that CD133+ tumor cells were cleared after cell infusion, which confirmed that CART-133 can home to the tumor lesions and specifically kill CD133+ cells in vivo; on the other hand, tumor recurrences maintained by cells expressed nontargeted antigen after CART-133 cells eliminate target expression cells. Further improvement of the cure rate of solid tumor by CART treatment and the avoidance of the rapid growth of antigen-negative cells after antigen-positive cell clearance is very important. In addition, T cell exhaustion is reportedly a significant barrier that limits the antitumor responses of engineered T cells in the setting of chronic antigen exposure.\textsuperscript{38} Refueling the exhausted CART cells via the PD-1/PD-L1 pathway using anti-PD-1 therapy is considered an important approach with potential benefit in solid tumors.\textsuperscript{39,40} One case report involved a PD-1 blocking antibody was administered to a patient with refractory diffuse large B-cell lymphoma after CART-19 cells infusion. Following PD-1 blockade, the patient had a clinically significant antitumor response, and a reexpansion of CART 19 cells.\textsuperscript{41} However, massive T cells infiltrated the tumor tissue after CART-133 cell treatment (Fig. 5A and B); the status suggested that combined anti-PD-1 therapy may augment the efficacy of CART-133 cells in
advanced solid tumors after CART cell infusion. In our other case report, one patient achieved a longer period of disease remission through treatment with CART-EGFR combined with CART-133 and anti-PD-1. We are evaluating the combination treatment of PD-1 antibody checkpoint blockade and CAR-directed T-cell therapy in our ongoing clinical trial.

In conclusion, adoptive immunotherapy with anti-CD133 CAR-modified T cells is a feasible and possibly effective treatment. Patients can achieve longer stable survival time or even partial remission of disease after CART-133 cell therapy. HCC patients with lower tumor burden or who maintain an early stage of tumor may have a favorable clinical response even with repeated CART-133 monotherapy. Finally, patients with biliary obstruction should be cautious during CART-133 treatment. These data will facilitate subsequent clinical trials to further augment the expansion, function, and persistence of CART-133 cells in the future.

Disclosure of potential conflicts of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding
National Key Research and Development Program of Chinas (No. 2016YFC1303501 and 2016YFC1303504) Science and Technology Planning Project of Beijing City (Z151100003915076) This study was supported by the grants from the National Key Research and Development Program of China (No. 2016YFC1303501 and 2016YFC1303504), the Science and Technology Planning Project of Beijing City (No. Z151100003915076).

References
1. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011;11:855–73. doi:10.1517/14712895.2011.573476. PMID:21463313.
2. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, DeMatteo RP, Ayala A, Joseph Espat N, Trump DL, et al. Live myocardial-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother. 2015;64:817–29. doi:10.1007/s00262-015-1692-6. PMID:25850344.
3. Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, Wang Y, Wang C, Shi Y, Qian P, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2015;155:160–75. doi:10.1016/j.clim.2014.10.002. PMID:25447722.
4. Guo Y, Wang Y, Han W. Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects. J Immunol Res. 2016;2016:8358039. doi:10.1155/2016/8358039. PMID:26998495.
5. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Cui S, Chen YY, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Ann Transl Med. 2016;4:92. doi:10.21037/atm.2016.03.03. PMID:26998495.
specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10:4. doi:10.1186/s13045-016-0378-7. PMID:28057014.

Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, Han W. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59:468–79. doi:10.1007/s11427-016-5023-8. PMID:26968708.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. doi:10.1016/j.ejca.2008.10.026. PMID:19097774.

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95. doi:10.1182/blood-2014-05-552729. PMID:24876563.

ruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66. doi:10.1016/S0140-6736(16)32453-9. PMID:27932229.

Weigmann A, Corbeil D, Hellwig A, Huttner WB, Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A. 1997;94:12425–30. doi:10.1073/pnas.94.23.12425. PMID:9356465.

Sotillo E, Barrett DM, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119–22. doi:10.1097/PPO.0000000000000035. PMID:24667956.

Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett. 2014;343:172–8. doi:10.1016/j.canlet.2013.10.004. PMID:24141191.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–4. doi:10.1126/science.1076514. PMID:12242449.

Kochenderfer JN, Somerville RP, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels. J Clin Oncol. 2017;35:1803–1813. JCO2016713024.

Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105:71–7. doi:10.1172/JCI8071. PMID:10619863.

Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med. 2005;56:79–101. doi:10.1146/annurev.med.56.090203.104149. PMID:15660503.

Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, Toso HW, Godec J, LaFleur MW, Brown FD, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354:1165–9. doi:10.1126/science.aae0491. PMID:27789799.

Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21:687–92. doi:10.1158/1078-0432.CCR-14-1860. PMID:25501578.

Zou W, Wolchok JD, Chen L. PD-1/L1 and PD-1–1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Science Translational Med. 2016;8:328rv4. doi:10.1126/scitranslmed.aad7118.

Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129:1039–41. doi:10.1182/blood-2016-09-738245. PMID:28031179.